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Abstract
Background Community-acquired pneumonia (CAP)
causes substantial clinical and economic burden. While
several studies have reported the cost to treat CAP, there is
little information on the cost to treat by age, risk profile,
and hospitalization in US adults aged C50 years.
Objective To quantify the cost, from a payer perspective,
of treating CAP at the episode level, stratified by age, risk
profile, and hospitalization.
Methods A retrospective study of claims data from a
large US health plan (1 January 2006–31 December
2008) was conducted. Patients aged C50 years having at
least one medical claim with a primary diagnosis for
pneumonia were identified. A CAP episode was defined
as the period between the first and last pneumonia ICD-9
code with a chest X-ray claim. Episode-level variables
included risk stratum based on presence of an immuno-
compromising/chronic condition, age group, number and
length of inpatient and outpatient CAP episodes, and all-
cause and CAP-related healthcare costs (adjusted to 2011
costs).
Results Among the 27,659 study patients, 28,575 CAP
episodes (20,454 outpatient; 8,121 inpatient) occurred.
Mean age of patients with a CAP episode was 62.6. Low-
risk patients accounted for 44.4 % of all CAP episodes.
Mean CAP episode length was 31.8 days for an inpatient
episode and 10.2 days for an outpatient episode. Mean
all-cause total healthcare cost for an inpatient CAP epi-
sode ranged from $11,148 to $51,219 depending on risk
stratum and age group. Mean outpatient episode-related
costs were much lower than inpatient episode-related
costs.
Conclusions Cost to treat CAP requiring hospitalization
is high regardless of age or the presence of underlying
comorbidities. Given that almost half of the patients in this
study did not have traditional risk factors for CAP, it is
clear that better preventative strategies are needed.
Key Points for Decision Makers:
• The cost of treating CAP requiring hospitalization is
high regardless of the presence of underlying
comorbidities or age, although the cost rises sub-
stantially with increasing level of risk.
• Despite trends toward greater use of outpatient versus
inpatient treatment, over a quarter of the commer-
cially insured CAP patients aged C50 years in this
study population were treated in a hospital setting.
• Even for low-risk patients in the 50- to 64-year age
group, hospitalization was quite costly, with a mean
cost of $15,385 (median $9,380).
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1 Background
Community-acquired pneumonia (CAP) is an acute infection
with potentially severe consequences, is associated with high
hospitalization and mortality rates, and results in consider-
able economic burden [1]. In the US, approximately 5.6
million cases of CAP occur each year with circa one-quarter
of those cases requiring hospitalization [2]. Roughly 1.3
million people in the US are admitted to the hospital with
CAP annually, and re-admission rates within the first 30 days
range from\1 to 20 % [3]. Among patients hospitalized for
pneumonia, approximately 10–20 % are admitted to an
intensive care unit [4, 5]. CAP is the sixth most common
cause of death [1], with a case-fatality rate of up to 16 % for
hospitalized CAP patients [6] and an overall 30-day mortality
rate ranging from 1 to 23 % [1].
Risk factors for CAP include advanced age and
comorbidities; these factors also increase the risk of
adverse outcomes for those diagnosed with CAP [3, 7, 8, 9,
10, 11]. In the older adult population, increasing age is
associated with an increase in CAP incidence [12, 13],
hospitalizations [13], and mortality [12, 13]. Among the
approximately 1.1 million people hospitalized for pneu-
monia (including CAP) in 2007, 21 % were aged
45–64 years, and 58 % were 65 or older [14]. To reduce
the risk for CAP, the Infectious Diseases Society of
America (IDSA) and the American Thoracic Society (ATS)
consensus guidelines recommend that persons aged
50 years and over receive a yearly vaccination with the
inactivated influenza virus and that persons aged 65 years
and older receive a pneumococcal vaccination [15].
In the US, the direct cost of CAP is reported to be in
excess of $17 billion annually [1]. However, the exact figure
is unknown and likely to be underestimated as the CAP cost
burden in the Medicare population alone was at least $13
billion in 2008 [16]. A separate study reported the annual
burden of CAP to be $10.6 billion in working-age adults in
2010 [17]. To provide context, $2.6 trillion was spent on
healthcare in the US in 2010 [18]. Estimated direct costs for a
single CAP-attributable outpatient visit ranging from $130 to
$4,500 were reported between the years 2000 and 2008 [19,
20, 21], conferring an annual cost of $9.3 billion (assuming 4
million outpatient CAP cases per year) [1, 20].
Although several studies have quantified the cost to treat
CAP, few have evaluated the cost to treat by age, risk
profile, and hospitalization in US adults. To address this
gap in the literature, the present study evaluated the eco-
nomic burden of CAP at the episode level in a sample of
commercially insured patients aged C50 years with CAP,
stratified by age, risk level, and inpatient versus outpatient
episode. The study was limited to patients aged 50 years
and older because of their higher risks for CAP [3, 7, 8, 9,
10, 11], the presence of increased comorbidities in this
population [8, 9], and the prevention strategies outlined by
the IDSA/ATS guidelines [15].
2 Methods
A retrospective study was conducted using integrated
administrative medical and pharmacy claims data from the
Optum Research Database, a large, proprietary US health
insurance database affiliated with Optum. At the time of
this study (2006–2007), approximately 13 million geo-
graphically diverse individuals with commercial medical
and pharmacy benefit coverage, and 8.6 million with
medical coverage only, were enrolled in this geographi-
cally diverse, commercially insured, national managed care
health plan. The health plan provides fully insured cover-
age for professional, facility, and outpatient prescription
medication services.
2.1 CAP Episode Identification
Patients with at least one medical claim with a primary
diagnosis of pneumonia were identified between 1 July
2006 and 31 December 2007. Pneumonia was identified
based on International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) codes of 480,
481, 482.xx-483.xx, 484.xx, 485, 486, and 487.0 from an
outpatient or inpatient venue. These codes have been used
in previously published studies to identify CAP [10, 14, 22,
23]. The service date of the first observed pneumonia claim
was defined as the index date. Patient inclusion criteria
were a chest X-ray claim within 14 days of the index date
(to distinguish CAP from other respiratory conditions),
aged 50 years or older, and continuous enrollment with full
benefits for at least 90 days prior to the start of the episode.
To refine CAP identification, patients were excluded if they
resided in a nursing home or other long-term care facility in
the 14 days prior to the index date or if they were hospi-
talized for any reason in the 14 days before the index date.
Demographic and clinical characteristics of patients with
CAP episodes were assessed during the pre-index period.
A CAP episode length was defined as the period
between the first medical claim with a primary diagnosis
for pneumonia (index date) and the last medical claim for
pneumonia in the primary or secondary position. The cutoff
for an episode start date was 15 December 2007 to allow
for at least 2 weeks of observation. Episodes that ended
beyond the date for which 90 days could be observed
between the last pneumonia medical claim and 31
December 2007 were censored at 31 December 2007.
Additionally, patients were required to have a 90-day
period free of pneumonia claims before and after the CAP
episode (clean-period), unless they died during the CAP
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episode (as determined from the LexisNexis ‘‘Accurint’’
database, which accesses Social Security Administration
death tapes) to distinguish one episode from another in the
same person and to ‘‘close’’ the episode period.
2.2 Healthcare Costs
All-cause total healthcare costs and CAP-related healthcare
costs [pharmacy, office visits, ambulatory visits, emer-
gency room (ER) visits, inpatient visits, and other costs]
were calculated by combining health plan and patient-paid
amounts incurred during each CAP episode. All-cause
costs were considered because CAP can exacerbate an
underlying medical condition, which may result in addi-
tional costs. CAP-related healthcare costs were also com-
puted based on medical claims of pneumonia in the
primary or secondary diagnosis position and any pharmacy
claims for antibiotics occurring within 2 days of a medical
claim for pneumonia. For an inpatient stay with a primary
or secondary pneumonia diagnosis, all the costs for the
particular hospital stay were attributed as CAP-related
costs. These data provide a good estimation of total costs of
care from a payer perspective, which is a key consideration
as payer-negotiated allowable amounts with providers
include combined health plan and patient-paid amounts.
The study focused on the costs of the episode as a whole
and not a cost comparison of individual procedures and
treatments. Costs were adjusted using the annual medical
care component of the Consumer Price Index (CPI) to
reflect inflation between 2007 and 2011 [24].
2.3 Stratification Variables
Because underlying factors such as age, comorbidity, and
setting of care lead to variation in the costs of treating
CAP, the data were stratified by these three variables. The
risk of developing CAP (low, moderate, high) was defined
based on the presence of immunocompromising or chronic
conditions [25, 26] at any time during the pre-episode clean
period through the end of the post-episode clean period.
High-risk patients had at least two claims falling within the
same condition, on separate dates, indicating a particular
immunocompromising condition [see Appendix A (elec-
tronic supplementary material) for relevant diagnosis/pro-
cedure codes and Appendix B (electronic supplementary
material) for relevant medications]. Patients were consid-
ered to be at moderate risk if they were immunocompetent
and had at least two medical claims falling within the same
condition, at least 30 days apart, with primary diagnoses
for a particular chronic condition [codes shown in
Appendix C (electronic supplementary material)]. Patients
not classified as moderate or high risk were considered to
be at low risk.
A CAP inpatient episode was defined as at least one
pneumonia-related (primary or secondary diagnosis) inpa-
tient stay; episodes not identified as inpatient were deemed
to be outpatient episodes. Age was stratified according to
the following: 50–64, 65–74, 75–84, and C85 years old.
2.4 Analyses
All study variables were analyzed descriptively and con-
ducted at an episode level. In addition to costs, other fac-
tors examined include episode length, length of hospital
stay including re-hospitalization for inpatient episode, and
cost components. Analyses were stratified by age, the set-
ting of care, and risk stratum.
3 Results
3.1 Patient Demographic and Clinical Characteristics
After applying all inclusion and exclusion criteria, there
were 27,659 patients who experienced 28,575 CAP epi-
sodes (Fig. 1). The vast majority of patients (97 %) had
only one episode during the CAP identification period.
Of the 28,575 CAP episodes, 28 % were treated in an
inpatient setting and 72 % were treated in an outpatient
setting. Across both treatment settings, the mean age of
patients with a CAP episode was 62.6 [SD 10.1] years, with
both genders represented equally (Table 1). Among the
inpatient CAP episodes, chronic obstructive pulmonary dis-
ease was the most common (36 %) chronic condition rep-
resented; among outpatient CAP episodes, diabetes was the
most prevalent chronic condition (15.3 %). Across both
treatment settings, 44.4 % of the total episodes occurred in
patients categorized as low-risk who did not have traditional
risk factors for CAP; however, the proportion of CAP epi-
sodes occurring in low-risk patients varied by treatment
setting, with 55.0 % of the outpatient CAP episodes and only
17.7 % of inpatient episodes occurring in low-risk patients.
3.2 Length of CAP Episode and Inpatient Stay
Overall, the mean CAP episode length was 31.8 [SD 47.6]
days for an inpatient episode and 10.2 [SD 23.7] days for
an outpatient episode (Fig. 2). In general, the episode
length increased with increasing age, reaching approxi-
mately 35 and 14 days for inpatient and outpatient epi-
sodes, respectively, for patients aged C75 years. The
episode length also increased with higher risk. For inpatient
episodes among patients aged C50 years, the mean [SD]
episode length was 24.7 [30.4], 30.5 [46.6], and 39.5 [57.3]
days for the low-, moderate-, and high-risk groups,
respectively. The median episode length was much lower:
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Fig. 1 Commercially insured patient attrition for community-acquired pneumonia (CAP) episode analyses occurring between 1 July 2006 and
31 December 2007







Mean SD Mean SD Mean SD
Age of patient with episode 62.55 10.12 61.44 9.45 65.35 11.15
n % n % n %
Age groups
50–64 19,639 68.73 14,960 73.14 4,679 57.62
65–74 4,424 15.48 2,983 14.58 1,441 17.74
75–84 3,048 10.67 1,785 8.73 1,263 15.55
85 and older 1,464 5.12 726 3.55 738 9.09
50 and older 28,575 100.00 20,454 100.00 8,121 100.00
65 and older 8,936 31.27 5,494 26.86 3,442 42.38
Gender
Female 14,494 50.72 10,564 51.65 3,930 48.39
Male 14,081 49.28 9,890 48.35 4,191 51.61
Risk stratum
Low 12,684 44.39 11,249 55.00 1,435 17.67
Moderate 11,131 38.95 6,570 32.12 4,561 56.16
High 4,760 16.66 2,635 12.88 2,125 26.17
Chronic condition
Heart failure 2,833 9.91 1,197 5.85 1,636 20.15
Diabetes 5,125 17.94 3,122 15.26 2,003 24.66
Asthma 3,010 10.53 1,968 9.62 1,042 12.83
Chronic obstructive pulmonary disease 6,025 21.08 3,104 15.18 2,921 35.97
Coronary artery disease 4,235 14.82 2,450 11.98 1,785 21.98
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14 days for an inpatient episode and 1 day for an outpatient
episode. This suggests that over half of the outpatient
episodes involved only one healthcare encounter.
Overall, the mean number of inpatient stays for a CAP
episode was 1.09 for patients C50 years of age. The overall
mean length of stay, which may have included any re-hos-
pitalization during the CAP episode, was 7.1 days. The
length of stay increased with increasing levels of risk, with a
mean of 4.8, 6.8, and 9.5 days for the low-, moderate-, and
high-risk groups, respectively, for patients aged C50 years.
3.3 All-Cause Healthcare Costs
The overall mean cost for an outpatient episode was $2,212,
but it was substantially higher for an inpatient episode
($27,661) (Fig. 3). For most age and risk groups, the cost of
an outpatient episode was about one-tenth to one-eighth of
the cost of an inpatient episode. As expected, the cost of an
episode rose with increasing risk within an age group.
However, even in the aged 50–64 years low-risk group, the
mean cost to treat CAP in a hospital setting was high at
$15,385 (Table 2). The median cost was much lower
($9,380), suggesting a skewed cost distribution. For both
outpatient and inpatient CAP episodes, there was a wider
range of mean costs across risk strata than across age groups.
For outpatient episodes, the majority of costs were due
to ambulatory visits and other medical costs, which include
non-pneumonia-related inpatient costs (Fig. 3). Pharmacy
costs comprised only 9.7 % of outpatient episode costs. For
inpatient episodes, 85.1 % of the all-cause costs were due
to inpatient care.
3.4 CAP-Related Healthcare Costs
CAP-related healthcare costs represented 93.2, 90.0, and
81.4 % of the all-cause total healthcare costs for inpatient
Fig. 2 Mean length of episode




Fig. 3 All-cause cost
components by treatment setting
(hospitalizations versus
outpatient) for episodes of
community-acquired
pneumonia (CAP) in patients
aged 50 years and older
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episodes for low-, moderate-, and high-risk patients aged
C50 years, respectively. For outpatient episodes, CAP-
related costs represented 55.7, 41.2, and 28.3 % of all-
cause total healthcare costs incurred by low-, moderate-,
and high-risk patients, respectively.
4 Discussion
CAP is a common respiratory illness and is a frequent
cause of hospitalization. In our study population of patients
aged C50 years, about 28 % of the CAP episodes required
an inpatient hospitalization. Low-risk patients had the
highest proportion of patients with an outpatient episode
among patients aged 50 years and over, and high-risk
patients had the highest proportion of patients with an
inpatient episode. The mean length of hospital stay
increased with age and risk level. Although the length of
stay was almost twice as long for the oldest age group
compared with the 50- to 64-year age group, a mean stay of
4.8 days constitutes a longer inpatient hospitalization than
one might expect with a relatively healthy younger age
group. In general, the older age groups have greater
comorbidity, so inpatient CAP-related stays would be
expected to be longer when underlying conditions are
being managed as well.
The mean numbers of inpatient days we observed are in
line with those cited in recent studies, which have reported
mean lengths of stay ranging from 4 to 12 days among
patients with CAP [3, 5, 27]. However, our mean lengths of
stay were longer than the national average reported in the
National Hospital Discharge Survey, where the average
length of stay for pneumonia discharges was 5.1 days in
patients aged 45–64 years and 5.4 days in patients aged
C65 years [14, 28]. We attribute the longer inpatient stays
in our study to the fact that our overall length of stay
included hospital days spent caring for pneumonia, non-
pneumonia-related complications or comorbidities, and any
re-hospitalization required within the same inpatient CAP
episode.
Patients who had an inpatient episode incurred high all-
cause and CAP-related total healthcare costs regardless of
age or risk stratum. The all-cause cost of an outpatient
episode was only a small fraction (8 %) of that of an
Table 2 All-cause total healthcare costs (US$) by age, risk stratum, and community-acquired pneumonia (CAP) treatment setting
Total healthcare costs Outpatient CAP episodes (N = 20,454) Inpatient CAP episodes (N = 8,121)
n Mean SD Median n Mean SD Median
Age 50–64 14,960 1,964 8,782 475 4,679 30,582 62,102 13,012
Low risk 9,212 1,048 3,752 412 940 15,385 24,785 9,380
Moderate risk 4,163 2,602 8,219 632 2,530 26,367 54,780 12,430
High risk 1,585 5,613 21,205 929 1,209 51,219 86,787 21,453
Age 65–74 2,983 2,530 7,800 532 1,441 25,578 45,276 11,675
Low risk 1,242 1,172 2,574 407 180 13,661 16,443 7,973
Moderate risk 1,195 2,810 6,984 656 822 22,550 40,472 11,096
High risk 546 5,003 14,158 890 439 36,134 58,064 16,310
Age 75–84 1,785 3,438 11,107 636 1,263 24,207 63,001 10,263
Low risk 538 1,394 4,047 358 175 11,148 11,812 7,756
Moderate risk 864 3,931 10,511 836 758 18,562 25,450 9,669
High risk 383 5,197 17,147 894 330 44,100 114,455 13,691
Age 85 and older 726 2,991 7,467 661 738 19,115 34,897 8,403
Low risk 257 2,023 5,806 397 140 15,336 36,384 6,323
Moderate risk 348 3,690 8,606 1,049 451 18,584 32,602 8,424
High risk 121 3,037 6,880 663 147 24,342 39,609 11,588
Age 50 and older 20,454 2,212 8,844 496 8,121 27,661 57,680 12,108
Low risk 11,249 1,100 3,719 409 1,435 14,647 24,151 8,822
Moderate risk 6,570 2,872 8,386 670 4,561 23,612 46,720 11,584
High risk 2,635 5,308 18,895 910 2,125 45,138 84,758 18,736
Age 65 and older 5,494 2,886 8,979 573 3,442 23,689 50,798 10,626
Low risk 2,037 1,338 3,560 394 495 13,246 22,857 7,697
Moderate risk 2,407 3,340 8,649 762 2,031 20,181 33,815 10,210
High risk 1,050 4,847 14,733 873 916 37,111 81,355 14,555
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inpatient episode, whereas inpatient stay was the predom-
inant cost component for an inpatient episode, comprising
85.1 % of the total cost. All-cause total healthcare costs
incurred by patients in the 50- to 64-year age group were
similar to those incurred by older patients such as those in
the 75- to 84-year age group. Even for low-risk patients in
the 50- to 64-year age group, hospitalization was quite
costly, with a mean cost of $15,385 (median $9,380).
The proportion of CAP-related costs decreased with
increasing risk stratum. This suggests that a greater propor-
tion of healthcare dollars was spent to treat underlying con-
ditions in higher risk patients than in low-risk patients.
Consistent with previously published results, we found that
CAP represents a substantial economic burden, particularly
when hospitalization becomes necessary [1, 20, 21]. Our
study is unique, however, in that we have stratified CAP
episode-level cost data by age and risk stratum. Stratifying
the analysis by risk level, based on the presence of an
immunocompromising or chronic condition, enabled us to
examine the impact of comorbidities on costs. The mean
incremental cost increase with each increasing risk stratum
was at least several thousand dollars for an inpatient episode.
While there was also variability in cost by age, that range of
costs was much narrower than the range observed across risk
groups, suggesting that comorbidities have greater impact
than age in determining cost outcomes for CAP.
4.1 Study Limitations
The limitations on the use of administrative claims data for
cost-of-illness studies are well recognized. Claims data are
collected for the purpose of payment and not research, and
are subject to possible coding errors, undercoding, and
coding for the purpose of ruling out a suspected disease
rather than determining the actual disease. Some of the
outpatient episodes could have been misclassified as
pneumonia when in fact they may have been respiratory-
related episodes, as half of the identified CAP patients had
an episode of only 1 day. However, it is clinically feasible
for mild CAP cases to have only one outpatient healthcare
encounter. Due to the robust sample size, small misclas-
sifications are unlikely to have substantially altered results.
While we did not validate the case definition of CAP in this
study, we used pneumonia codes from similar previous
studies [10, 14, 22, 23] and applied additional criteria to
better identify CAP.
The definition of length of episode duration used in this
study may have resulted in longer illness duration than
what is typically observed in clinical practice and therefore
may have resulted in overestimation of costs. Although
there is evidence to support the fact that CAP symptoms
linger well beyond the period of antibiotic prescription
[29], we captured episode duration by economic resource
use based on pneumonia-related claims, rather than from a
strict clinical perspective.
Our study population was a sample of managed care
enrollees; therefore, results may not be generalizable to
other populations. Finally, the data used for this study
pertain to costs of CAP episodes incurred in 2007 and
therefore may not accurately represent current cost pat-
terns. However, we CPI-adjusted episode level costs to
2011 dollars.
Despite these limitations, administrative data allow for
examination of healthcare utilization and expenditure pat-
terns in a real-world setting and offer the advantage of
large sample sizes with diverse medical histories.
5 Conclusions
Hospitalization is the most costly factor in the management
of CAP. Despite trends toward greater use of outpatient
versus inpatient treatment, over a quarter of these com-
mercially insured CAP patients aged C50 years were
treated in a hospital setting. Cost to treat CAP requiring
hospitalization is high regardless of the presence of
underlying comorbidities or age, although the cost rises
substantially with increasing level of risk. Given that
almost half (44 %) of the CAP patients in this study did not
have traditional risk factors for CAP, it is clear that efforts
to better implement preventative strategies as recom-
mended by IDSA/ATS CAP management guidelines
[15]—i.e., vaccination targeting influenza and pneumo-
coccal disease for older adults and for individuals with
medical conditions that place them at high risk for pneu-
monia morbidity and mortality—are needed to reduce the
incidence and economic burden of CAP.
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